| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of 1 Neurology and 2 Immunology, and 3 Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota
Purpose: Determine muscle and neuronal autoantibody frequencies in patients with thymoma, with and without paraneoplastic neurological accompaniments.
Experimental Design: Analysis of IgG autoantibodies in stored serum collected between 1985 and 2003 from 201 patients with histologically diagnosed thymoma (including six with thymic carcinoma). Contemporary assays quantitated antibodies reactive with muscle and neuronal cation channels, muscle sarcomeric proteins and neuronal cytoplasmic, and nuclear proteins.
Results: Neurological diagnoses included myasthenia gravis (MG), myositis, encephalitis, neuromuscular hyperexcitability, autonomic neuropathy, and subacute hearing loss, a previously unrecognized accompaniment of thymoma. Muscle acetylcholine receptor (AChR) binding antibodies were found in all patients with a diagnosis of MG. Muscle autoantibodies (AChR-binding, AChR-modulating, or striational) were also found in 59% of patients without any neurological disorder. One or more neuronal autoantibodies were found in 41% of patients without any neurological disorder, 43% of patients with MG only, and 78% of patients with other neurological disorders. Neuronal autoantibody specificities were, in descending order of frequency, as follows: glutamic acid decarboxylase, voltage-gated potassium channel, collapsin response-mediator protein-5, ganglionic AChR, and antineuronal nuclear antibody-type 1 (ANNA-1).
Conclusions: Neuronal autoantibodies complement skeletal muscle autoantibodies as serological markers of thymoma in patients with and without clinical evidence of a neurological disorder. The high prevalence of glutamic acid decarboxylase autoantibody, not previously considered a paraneoplastic marker, justifies its consideration as a marker of thymoma-related neurological autoimmunity. Serological evaluation of a patient’s profile of neuronal and muscle autoantibodies may aid in preoperative identification of an indeterminate mediastinal mass.
This article has been cited by other articles:
|
|
 |
|
  S E Monstad, J K Nostbakken, and C A Vedeler CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis J. Neurol. Neurosurg. Psychiatry, February 1, 2009; 80(2): 241 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. McKeon, J. E. Ahlskog, J. A. Britton, V. A. Lennon, and S. J. Pittock Reversible Extralimbic Paraneoplastic Encephalopathies With Large Abnormalities on Magnetic Resonance Images Arch Neurol, February 1, 2009; 66(2): 268 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Saiz, Y. Blanco, L. Sabater, F. Gonzalez, L. Bataller, R. Casamitjana, L. Ramio-Torrenta, and F. Graus Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association Brain, October 1, 2008; 131(10): 2553 - 2563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gesundheit, B. Lerer, E. Budowski, T. Neuman, J. M Gomori, and R. Or Sudden Psychotic Symptoms in a 28-Year-Old Male With Thymoma J. Clin. Oncol., September 10, 2008; 26(26): 4353 - 4355. [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Tan, V. A. Lennon, C. J. Klein, B. F. Boeve, and S. J. Pittock Clinical spectrum of voltage-gated potassium channel autoimmunity Neurology, May 13, 2008; 70(20): 1883 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vernino, P. Sandroni, W. Singer, and P. A. Low Invited Article: Autonomic ganglia: Target and novel therapeutic tool Neurology, May 13, 2008; 70(20): 1926 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Pittock and V. A. Lennon Aquaporin-4 Autoantibodies in a Paraneoplastic Context Arch Neurol, May 1, 2008; 65(5): 629 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Hajdu and P. Tang The Saga of Carcinoid and Oat-Cell Carcinoma Ann. Clin. Lab. Sci., January 1, 2008; 38(4): 414 - 417. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Pittock, H. Yoshikawa, J. E. Ahlskog, S. H. Tisch, E. E. Benarroch, T. J. Kryzer, and V. A. Lennon Glutamic Acid Decarboxylase Autoimmunity With Brainstem, Extrapyramidal, and Spinal Cord Dysfunction Mayo Clin. Proc., September 1, 2006; 81(9): 1207 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Riedel and W. R. Burfeind Jr Thymoma: Benign Appearance, Malignant Potential Oncologist, September 1, 2006; 11(8): 887 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hernandez-Echebarria, A. Saiz, A. Ares, J. Tejada, L. Garcia-Tunon, C. Nieves, and F. Graus Paraneoplastic encephalomyelitis associated with pancreatic tumor and anti-GAD antibodies Neurology, February 14, 2006; 66(3): 450 - 451. [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Vinik, D. Anandacoomaraswamy, and J. Ullal Antibodies to Neuronal Structures: Innocent bystanders or neurotoxins? Diabetes Care, August 1, 2005; 28(8): 2067 - 2072. [Full Text] [PDF]
|
|
|
|
|
|
C. Antozzi, C. Frassoni, A. Vincent, M. C. Regondi, F. Andreetta, P. Bernasconi, C. Ciano, T. Chang, F. Cornelio, R. Spreafico, et al. Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia Neurology, April 12, 2005; 64(7): 1290 - 1293. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
